GlaxoSmithKline PLC (NYSE:GSK) saw an uptick in trading volume on Friday . 2,423,045 shares traded hands during mid-day trading, a decline of 1% from the previous session’s volume of 2,456,452 shares.The stock last traded at $44.26 and had previously closed at $42.98.

A number of brokerages have commented on GSK. Shore Capital restated a “hold” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, August 17th. Argus upped their price target on GlaxoSmithKline PLC from $48.00 to $50.00 and gave the stock a “buy” rating in a research note on Friday, August 12th. Citigroup Inc. reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, August 10th. Beaufort Securities reiterated a “buy” rating on shares of GlaxoSmithKline PLC in a research note on Tuesday, August 2nd. Finally, BNP Paribas reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Sunday, July 31st. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Hold” and an average price target of $47.19.

The stock has a 50-day moving average price of $44.26 and a 200 day moving average price of $42.20. The company has a market capitalization of $107.57 billion and a price-to-earnings ratio of 2766.25.

The business also recently announced a dividend, which will be paid on Thursday, October 13th. Investors of record on Friday, August 12th will be given a $0.494 dividend. The ex-dividend date is Wednesday, August 10th.

A hedge fund recently raised its stake in GlaxoSmithKline PLC stock. US Bancorp DE increased its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 6.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 384,500 shares of the pharmaceutical company’s stock after buying an additional 22,162 shares during the period. US Bancorp DE’s holdings in GlaxoSmithKline PLC were worth $15,514,000 at the end of the most recent reporting period.

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.